BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28720764)

  • 1. High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis.
    Kawabata KC; Hayashi Y; Inoue D; Meguro H; Sakurai H; Fukuyama T; Tanaka Y; Asada S; Fukushima T; Nagase R; Takeda R; Harada Y; Kitaura J; Goyama S; Harada H; Aburatani H; Kitamura T
    Leukemia; 2018 Feb; 32(2):419-428. PubMed ID: 28720764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.
    Shirahata-Adachi M; Iriyama C; Tomita A; Suzuki Y; Shimada K; Kiyoi H
    Leuk Res; 2017 Dec; 63():90-97. PubMed ID: 29127861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
    Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
    Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation.
    Sashida G; Harada H; Matsui H; Oshima M; Yui M; Harada Y; Tanaka S; Mochizuki-Kashio M; Wang C; Saraya A; Muto T; Hayashi Y; Suzuki K; Nakajima H; Inaba T; Koseki H; Huang G; Kitamura T; Iwama A
    Nat Commun; 2014 Jun; 5():4177. PubMed ID: 24953053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a Novel Myelodysplastic Syndrome (MDS) Xenotransplantation Model.
    Ma L; Zhang X; Wang Z; Chen Y; Wei J; Hu L
    Clin Lab; 2016 Sep; 62(9):1651-1659. PubMed ID: 28164571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of enhancer of zeste homolog 2 mutations on the prognosis of patients with myelodysplastic syndrome: A meta-analysis.
    Huang X; Wang X
    Medicine (Baltimore); 2020 Aug; 99(34):e21900. PubMed ID: 32846854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant Expression of
    de Souza Fernandez T; Fonseca Alvarenga T; Almeida Antônio de Kós E; Lamim Lovatel V; Tavares RC; da Costa ES; de Souza Fernandez C; Abdelhay E
    Biomed Res Int; 2019; 2019():3176565. PubMed ID: 31886200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2).
    Ma L; Zhang X; Wang Z; Huang L; Meng F; Hu L; Chen Y; Wei J
    Curr Cancer Drug Targets; 2019; 19(9):729-741. PubMed ID: 30747066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal shifts in MDS - from SF3B1 to EZH2.
    Barbosa Ribeiro A; Coucelo M; Tenreiro R; Simões AT; Marques G; Ribeiro L; Cortesão E; Sarmento-Ribeiro AB
    Leuk Lymphoma; 2018 Dec; 59(12):2994-2997. PubMed ID: 29616853
    [No Abstract]   [Full Text] [Related]  

  • 10. HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia.
    He Z; Zhang S; Ma D; Fang Q; Yang L; Shen S; Chen Y; Ren L; Wang J
    J Transl Med; 2019 Nov; 17(1):366. PubMed ID: 31711520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.
    Muto T; Sashida G; Oshima M; Wendt GR; Mochizuki-Kashio M; Nagata Y; Sanada M; Miyagi S; Saraya A; Kamio A; Nagae G; Nakaseko C; Yokote K; Shimoda K; Koseki H; Suzuki Y; Sugano S; Aburatani H; Ogawa S; Iwama A
    J Exp Med; 2013 Nov; 210(12):2627-39. PubMed ID: 24218139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dyserythropoiesis in myelodysplastic syndrome].
    Iwama A
    Rinsho Ketsueki; 2018; 59(10):2036-2041. PubMed ID: 30305506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of EZH2 expression in myelodysplastic syndromes.
    Cabrero M; Wei Y; Yang H; Ganan-Gomez I; Bohannan Z; Colla S; Marchesini M; Bravo GM; Takahashi K; Bueso-Ramos C; Garcia-Manero G
    Leuk Res; 2016 May; 44():1-7. PubMed ID: 26970171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes.
    Sakhdari A; Class C; Montalban-Bravo G; Sasaki K; Bueso-Ramos CE; Patel KP; Routbort MJ; Loghavi S; Ok CY; Quesada A; Khoury JD; Konoplev SN; Kantarjian HP; Garcia-Manero G; Medeiros LJ; Kanagal-Shamanna R
    Mod Pathol; 2022 Sep; 35(9):1212-1219. PubMed ID: 35504958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
    Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
    Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ineffective erythropoiesis in myelodysplastic syndrome].
    Iwama A
    Rinsho Ketsueki; 2018; 59(6):793-797. PubMed ID: 29973461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epigenetic dysregulation in myelodysplastic syndromes].
    Sashida G
    Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.
    Nikoloski G; Langemeijer SM; Kuiper RP; Knops R; Massop M; Tönnissen ER; van der Heijden A; Scheele TN; Vandenberghe P; de Witte T; van der Reijden BA; Jansen JH
    Nat Genet; 2010 Aug; 42(8):665-7. PubMed ID: 20601954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
    Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
    Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes.
    McGraw KL; Nguyen J; Al Ali NH; Komrokji RS; Sallman D; Zhang X; Song J; Padron E; Lancet JE; Moscinski LC; List AF; Zhang L
    Br J Haematol; 2019 Feb; 184(3):450-455. PubMed ID: 29359794
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.